Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cingulate Inc ( (CING) ) has provided an announcement.
Cingulate Inc. announced the completion of its final FDA-required food effect study for CTx-1301, a medication intended for the treatment of ADHD. The study showed no serious adverse events, and a data readout on bioavailability is expected in the second quarter of 2025, with a New Drug Application submission targeted for mid-2025. This milestone is significant for Cingulate, as CTx-1301 aims to provide a once-daily stimulant medication that effectively covers an entire active day, enhancing treatment options for ADHD patients.
More about Cingulate Inc
Cingulate Inc. is a biopharmaceutical company that employs its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop next-generation pharmaceutical products. The company’s initial focus is on the treatment of Attention Deficit Hyperactivity Disorder (ADHD), with plans to explore other therapeutic areas such as anxiety disorders.
YTD Price Performance: -2.55%
Average Trading Volume: 138,534
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.96M
Learn more about CING stock on TipRanks’ Stock Analysis page.
